期刊
CANCER DISCOVERY
卷 10, 期 4, 页码 608-625出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-19-0297
关键词
-
类别
资金
- CPRIT Proteomics [P30CA16672, P30CA125123]
- NCI [RP170005]
- DOD Postdoctoral Research Fellowship [P01 CA117969, NCI R01 CA225955]
- CPRIT Research Training Program [W81XWH-14-1-0429, K99/R00, 1K99 CA218891-01A1, U24 CA224020, R01 CA218004, R01 CA304969]
- [RP140106]
- [170067]
A hallmark of pancreatic ductal adenocarcinoma (PDAC) is an exuberant stroma comprised of diverse cell types that enable or suppress tumor progression. Here, we explored the role of oncogenic KRAS in protumorigenic signaling interactions between cancer cells and host cells. We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2r gamma-IL4r alpha and IL2r gamma-IL13r alpha 1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2 cells producing IL4 and IL13. Activated IL2r gamma-IL4r alpha and IL2r gamma-IL13r alpha 1 receptors signal primarily via JAK1-STAT6. Integrated transcriptomic, chromatin occupancy, and metabolomic studies identified MYC as a direct target of activated STAT6 and that MYC drives glycolysis. Thus, paracrine signaling in the tumor microenvironment plays a key role in the KRAS*-driven metabolic reprogramming of PDAC. SIGNIFICANCE: Type II cytokines, secreted by Th2 cells in the tumor microenvironment, can stimulate cancer cell-intrinsic MYC transcriptional upregulation to drive glycolysis. This KRAS*-driven heterotypic signaling circuit in the early and advanced tumor microenvironment enables cooperative protumorigenic interactions, providing candidate therapeutic targets in the KRAS* pathway for this intractable disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据